To improve ART initiation among people who inject drugs, the investigators propose to develop and pilot a multi-component Integrated Methadone and Antiretroviral Therapy strategy (IMAT) in Dar es Salaam, Tanzania. In doing so, the investigators anticipate building a functional model of methadone and ART integration that improves the effectiveness and efficiency of service delivery.
The overarching goal of the proposed research is to develop and test an innovative implementation model (IMAT) for the effective integration of HIV care and treatment with methadone services in Dar es Salaam, Tanzania. The investigators will utilize the PRECEDE framework to inform the intervention to improve linkage of HIV-positive methadone patients to ART. This model suggests that strategies intended to improve health care delivery should consider a combination of three factors: 1) 'predisposing factors' - characteristics such as knowledge, attitudes, beliefs and motivation to change, 2) 'enabling factors' - characteristics that enable someone to act on their desired behavior and 3) 'reinforcing factors' - factors that encourage repetition or persistence of behavior. Therefore, our IMAT approach uses 1) targeted education and mentoring for providers that predispose them to timely ART initiation, 2) POC CD4 count platforms (PIMA, Alere) providing real-time screening and results that enable ART initiation and 3) an alerts and reminder dashboard (e.g., a summary of key indicators for improved decision making) for providers that reinforce ART initiation. Additionally, our approach will lay the foundation for developing implementation strategies for future point-of-care technologies such as viral load. The study will combine a mixture of qualitative and quantitative methodologies to inform and evaluate the IMAT intervention. A baseline qualitative study using in-depth interviews will be conducted among providers and methadone clients to understand predisposing, enabling and reinforcing factors related to integration of HIV care and treatment into the methadone clinic. Information gained from these qualitative assessments will inform and support the IMAT strategy. In addition, HIV-positive methadone clients will be randomly selected to complete a baseline cross-sectional survey to collect data on patient satisfaction, access to HIV care, current treatment navigation access, and HIV care literacy. The investigators will assess the effectiveness of IMAT with a quasi-experimental pre-post cohort design and a pre-post cross-sectional survey to examine changes in patient- and provider-level outcomes after implementation of IMAT compared to before IMAT. In addition, The investigators will assess the feasibility and acceptability of the IMAT strategy using a post-implementation cross-sectional survey with a particular emphasis on satisfaction with services; a time motion study to understand the timeliness of care provision; and in-depth interviews with patients and providers to understand experiences with the IMAT strategy.
Study Type
OBSERVATIONAL
Enrollment
800
The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
Time to CD4 Screening
Number of days between positive HIV test and CD4 screening. Extracted from routine clinical and laboratory monitoring data.
Time frame: Up to 36 months
Provider Time to Ordering CD4 Screening
Collected via routine, programmatic data
Time frame: Up to 36 months
Percentage of clients that receive CD4 screening within 30 days of HIV-positive test
Collected via routine, programmatic data
Time frame: Up to 36 months
Percentage of eligible (CD4<350) clients that initiate ART within 30 days of CD4 screening
Collected via routine, programmatic data
Time frame: Up to 36 months
Percentage of clients on ART that receive at least 95% ART doses (i.e., adherence)
Collected via routine, programmatic data
Time frame: Up to 36 months
Percentage of patients receiving HIV treatment navigation counseling from provider
Collected via cross-sectional surveys pre- and post-intervention.
Time frame: Three months pre-intervention and three months post-intervention
Percentage of patients literate in CD4 screening process
Collected via cross-sectional surveys pre- and post-intervention.
Time frame: Three months pre-intervention and three months post-intervention
Percentage of patients literate in ART Initiation process
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Collected via cross-sectional surveys pre- and post-intervention.
Time frame: Three months pre-intervention and three months post-intervention
Time to ART Initiation
Number of Days between receiving a qualifying CD4 count and first dose of ART. Extracted from routine clinical and laboratory monitoring data.
Time frame: Up to 36 months